Answers, in depth.

Care is directed by board-certified physicians with sports- medicine and endocrine training. Each patient has a single named clinician across hormones, peptides, and metabolic protocols — not a different prescriber every renewal. See the about page for the founding team.

Hormone optimization (men's TRT, enclomiphene, women's HRT), peptide therapy (sermorelin, CJC/Ipa, BPC-157, tesamorelin, NAD+, GHK-Cu, thymosin, glutathione, methylene blue), GLP-1 metabolic therapy (semaglutide, tirzepatide), sexual wellness, and hair restoration. Full catalog at /treatments.

Hone is hormone-only. Henry Meds and Hims are quiz-funnel scale plays with limited peptide menus and rotating prescribers. Marek is concierge but costs $2,500–$4,000 year one and explicitly excludes NJ/NY/RI. Vektor sits in the gap: full peptide + hormone + GLP-1 menu, single clinician model, $149/mo founding tier. The trade-off is intentional.

You complete a structured intake (about 15 minutes), then book a 30-minute video consult with your physician. Real video — not an async form. Your physician reviews your history, asks the questions a script can't ask, and orders baseline labs. Follow-up consult to design your protocol after labs return.

Your physician sends a lab order to your nearest Quest or LabCorp draw center. You walk in, get drawn (no appointment needed at most locations), and results return within 3–5 business days. Your physician then reviews them with you on a video call line-by-line — not via a PDF in your inbox. Repeat labs at 8–12 weeks after protocol changes, then quarterly.

Yes. Direct messaging with your clinician is part of membership. Routine questions get same-day responses during business hours. Urgent clinical questions get escalated immediately. No chatbot funnel, no first-tier support layer — you message the person prescribing your protocol.

Physician access (consults + direct messaging), lab orders (you pay the draw center directly — typically $50–250 per panel), quarterly check-ins with the medical director, and a single coordinated chart across every therapy you're on. Medications are priced separately at fair retail. See /pricing for the full breakdown.

From $159/mo for Sermorelin, $249/mo for CJC-1295/Ipamorelin, $89/mo for testosterone cypionate, $179/mo for compounded semaglutide, $229–$269/mo for BPC-157 protocols. Full per-protocol pricing on /pricing.

Sometimes — it depends on your plan's definition of eligible expenses and the clinical indication. Membership fees and labs are usually eligible. Compounded medications vary by plan. We provide itemized receipts you can submit to your HSA/FSA administrator. We do not bill HSA/FSA directly.

Not today. The founding-100 waitlist holds your spot at no cost. Billing only begins when launch goes live in your state and you activate your care plan. You can decline activation anytime. The locked $149/mo founding rate doesn't expire while your state is pending.

We don't bill insurance. Membership fees and most compounded medications are cash-pay. The trade-off is real: insurance gates the clinician model toward 7-minute visits and tightly restricted formularies. The cash-pay model lets us run the cadence the medicine actually needs.

For branded GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro), insurance coverage is plan-dependent and increasingly restrictive. Your physician can write a prescription you fill at any pharmacy that accepts your insurance. We'll also quote compounded semaglutide / tirzepatide where the FDA 503A pathway permits, so you can compare cash-pay vs insurance- billed cost.

We can submit prior authorization paperwork for branded GLP-1s when patients want to try the insurance route. PA outcomes depend on your plan and indication. We'll be honest about likely success before you spend the time.

Both are FDA-regulated U.S. compounding pharmacies. 503A pharmacies compound for individual prescriptions; 503B pharmacies operate as outsourcing facilities and compound at commercial scale. Both are LegitScript-certifiable. Vektor uses both depending on the medication. Neither is a research- chemical supplier — that's a separate, unregulated category we don't engage with.

For GLP-1s, compounded options often cost a fraction of branded equivalents (Wegovy + Zepbound list around $1,000– $1,900/mo without insurance) and may be the only accessible option when branded is on FDA shortage. For peptides, compounded is the only legal route — most peptides don't have a branded FDA-approved equivalent. We prescribe branded when it's the right choice; we don't default to it.

Medications ship directly from our 503A/503B pharmacy partners to your address — typically overnight or 2-day, refrigerated where required (most peptides ship in cold packs). Subscriptions auto-refill on the cadence your physician set; you can pause or stop any time.

No. We don't prescribe peptides that haven't cleared FDA Phase II/III trials. Retatrutide and cagrilintide are still in clinical development. Epitalon and MOTS-c have no FDA approval pathway. Our scope is FDA-approved drugs and compounded peptides on the legitimate 503A list — not the research-chemical gray market.

Yes — when prescribed by a licensed physician through a legitimate U.S. 503A compounding pharmacy. Vektor's entire model is built around that compliance posture. The unlicensed “research peptide” sites you may have seen in search results operate outside that framework and are not the same thing.

Exogenous testosterone suppresses the body's LH/FSH signal, which suppresses spermatogenesis. For patients who want to preserve fertility, we add gonadorelin (or hCG when available) to maintain testicular function. Patients actively trying to conceive need a different protocol — usually enclomiphene-led rather than TRT. See the enclomiphene vs TRT article.

Most common: nausea, early satiety, constipation. They're usually transient and dose-dependent. We start at the lowest therapeutic dose and titrate slowly, which mitigates most of them. Hydration and protein intake guidance is part of the protocol. Direct physician messaging means side-effect questions don't wait for the next monthly visit.

For diagnostic purposes, no — most consumer hormone tests don't use sensitive-assay methodology (LC-MS/MS), which matters especially for male estradiol. We use proper clinical- grade panels at Quest or LabCorp. Bring any prior testing you've done — it's useful directional data even if we'll re-run the panel ourselves.

Yes. Clinical intake and care happen on HIPAA-compliant infrastructure with signed Business Associate Agreements (BAAs) across every vendor that touches Protected Health Information. The marketing site you're reading does not collect PHI — name and email only, no health questions.

Your physician and the supporting clinical team — nurses, care coordinators — who are bound by HIPAA. We don't share clinical data with marketing partners, ad platforms, or anyone outside the care team unless you explicitly authorize it (e.g., asking us to send a summary to your PCP).

Yes — see our Privacy Policy. You can request deletion of marketing data (name, email) anytime. Clinical records have separate retention rules under state medical-records law; we can't delete a chart we were required to maintain, but we can hand it over or close the account.

We're anchored in the NJ/NY area and expanding state-by-state to all 50 U.S. states. Reserving a founding spot locks the $149/mo rate even if your state goes live months later. Live state pages are listed on the about page.

FDA 503A compounding is a real, regulated category — but it evolves. Some peptides move on and off the compoundable list based on clinical evidence and supply considerations. We'll tell you transparently if a specific medication isn't available right now under the current 503A posture. Our pharmacy partners track regulatory updates in real time.

You must be physically located in a state where your physician is licensed at the time of the appointment. Brief domestic travel is fine — just confirm where you'll be when we schedule. International travel during a consult is not currently supported.